DNMT1 and p-STAT3 (downstream factors of RCC2) are implicated in therapeutic resistance in GBM tumor cells by functioning in an epistatic manner with RCC2 (Yu et al., 2019). This evidence concerns the gene STAT3 and neoplasm.